A new antibody drug demonstrated similar efficacy to currently available therapies to treat advanced ERBB2-positive breast cancer, according to a recent clinical trial.
Abbey Filicko, a third-year medical student, presented findings from her community-based participatory research project in partnership with Chicago Public Schools at this year’s American Public Health Association (APHA) virtual annual meeting.
A team led by Northwestern Medicine investigators has identified a novel molecular target that may improve the efficacy of current treatments for triple-negative breast cancer.
Take a look back at a handful of groundbreaking research discoveries that marked one of, if not the most, unprecedented and transformative years for Feinberg.
A multi-institution team of investigators led by Northwestern Medicine scientists has received an $8 million grant for the identification of novel biological targets to develop non-hormonal contraceptives for women in developing countries.
Targeting the proteins CD47 and HER2 may eliminate radioresistant breast cancer cells and enable more effective radiotherapy treatments for patients, according to a new study.
William Grobman, MD, MBA, ’97 ’00 GME, vice chair for clinical operations and the Arthur Hale Curtis, MD, Professor of Obstetrics and Gynecology, has been elected to the National Academy of Medicine.
The drug rucaparib significantly delayed cancer progression for women with ovarian cancer and may be an effective option for maintenance therapy, according to findings from a recent clinical trial.
Biological sex has a small but ubiquitous influence on gene expression in almost every type of human tissue, according to a new study.
A new combination therapy targeting breast cancer tumors in the brain dramatically decreased tumor size and increased survival in mice, according to a new study.